Clinical Trial Update: First in Patient Study for PF-06840003 in Malignant Gliomas [Phase 1]

View source ↗

Summary

Phase 1 trial update for PF-06840003 in malignant gliomas has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Malignant Glioma
• Oligodendroglioma

Drugs mentioned

• PF-06840003

Snippet

Sponsor: Pfizer | Conditions: Oligodendroglioma, Astrocytoma | Phase 1 | Status: TERMINATED | Results posted: 2020-01-27